Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it

Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it

Source: 
Endpoints
snippet: 

In 2016, Dova Pharmaceuticals paid Japan’s Eisai a paltry $5 million upfront for the rights to the Phase III-ready avatrombopag. The following year, the Durham, North Carolina-based company made its public debut with a $75 million IPO, and by 2018 the drug — branded as Doptelet — secured FDA approval. Dova’s bet paid off handsomely — on Monday, the company unveiled Swedish Orphan Biovitrum AB was acquiring its shares in a deal worth up to a robust $915 million.